Home > Prices, Research & Announcements > Announcements > Announcements - Search results

• Print page

Announcements - Search results

Search results: Company announcements for
VIRALYTICS LIMITED (VLA)
Released between 01/01/2009 and 31/12/2009

Didn't find the announcement you were after? > Search again.

Announcements released as VLA

Date	Price sens.	Headline	Pages	PDF	Edited text*
18/12/2009		Head and Neck trial dosing increase	2	PDF	-
11/12/2009		Share Registry - Change of Address	1	PDF	-
02/12/2009		Appendix 3B	8	PDF	-
30/11/2009		Change of Director`s Interest Notice	2	PDF	-
24/11/2009		Results of 2009 Annual General Meeting	2	PDF	-
24/11/2009		Managing Director`s address to the 2009 AGM	3	PDF	-
23/11/2009		Leading UK Oncologist joins VLA Clinical Advisory Board	2	PDF	-
20/11/2009		Section 708A(5)(e) Notice	1	PDF	-
20/11/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
19/11/2009		Section 708A(5)(e) Notice	1	PDF	-
19/11/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
19/11/2009		Viralytics Limited - Share Price Movement	1	PDF	-
11/11/2009		US Corporate Presentation by VLA Managing Director	30	PDF	-
10/11/2009		Section 708A(5)(e) Notice	1	PDF	-
10/11/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
06/11/2009		Leading US Virologist joins VLA Clinical Advisory Board	1	PDF	-
02/11/2009		Melanoma, Breast and Prostate cancer IV trial - 2nd site	2	PDF	-
30/10/2009		Appendix 4C - quarterly	4	PDF	-
29/10/2009		Head and Neck cancer study additional site - Royal Adelaide	2	PDF	-
23/10/2009		Notice of Annual General Meeting and Annual Report	72	PDF	-
19/10/2009		Section 708A(5)(e) Notice	1	PDF	-
19/10/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
12/10/2009		Section 708A(5)(e) Notice	1	PDF	-
12/10/2009		Appendix 3B - Partial Conversion of Convertable Note	8	PDF	-
08/10/2009		Head and Neck Trial Update	1	PDF	-
30/09/2009		Annual Report to shareholders	62	PDF	-
24/09/2009		Appendix 3B partial conversion of Convertible Note	8	PDF	-
24/09/2009		Section 708A(5)(e) Notice	1	PDF	-
22/09/2009		Melanoma trial completed	2	PDF	-
15/09/2009		Section 708A(5)(e) Notice	1	PDF	-
15/09/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
31/08/2009		Section 708A(5)(e) Notice	1	PDF	-
31/08/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
31/08/2009		Preliminary Final Report and FY2009 Statutory Accounts	63	PDF	-
24/08/2009		Section 708A(5)(e) Notice	1	PDF	-
24/08/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
21/08/2009		Share Registry - Change of Address	1	PDF	-
21/08/2009		Results of Extraordinary General Meeting	1	PDF	-
13/08/2009		Clinical Trial progress	3	PDF	-
29/07/2009		Section 708A(5)(e) Notice	1	PDF	-
29/07/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
29/07/2009		Appendix 4C - quarterly	5	PDF	-
21/07/2009		Section 708A(5)(e) Notice	1	PDF	-
21/07/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
17/07/2009		Section 708A(5)(e) Notice	1	PDF	-
17/07/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
15/07/2009		Notice of Meeting and Independent Expert`s Report	82	PDF	-
09/07/2009		Section 708A(5)(e) Notice	1	PDF	-
09/07/2009		Appendix 3B - Partial Conversion of Convertible Note	8	PDF	-
01/07/2009		Options Rights Issue Result and Capital Raising Update	3	PDF	-
01/07/2009		Appendix 3B	7	PDF	-
17/06/2009		Mailing to Shareholders	9	PDF	-
17/06/2009		Appendix 3B - Convertible Note	9	PDF	-
12/06/2009		$US6m convertible note facility signed	2	PDF	-
01/06/2009		Supplementary Prospectus	4	PDF	-
01/06/2009		Supplementary Prospectus issued and funding offer received	2	PDF	-
25/05/2009		Non-Renounceable Issue - offer period extended	2	PDF	-
08/05/2009		Despatch of Prospectus	2	PDF	-
29/04/2009		Appendix 4C - quarterly	5	PDF	-
22/04/2009		Sample Letters to Shareholders and Optionholders	5	PDF	-
22/04/2009		Appendix 3B - Non-Renounceable Options Rights Issue	7	PDF	-
22/04/2009		Non-Renounceable Options Rights Issue	39	PDF	-
20/04/2009		IV breast prostate and melanoma trial dosage increase	1	PDF	-
30/03/2009		Viralytics strengthens US patent portfolio	1	PDF	-
20/03/2009		International Conference Presentation	35	PDF	-
13/03/2009		Placement of shares and Appendix 3B	8	PDF	-
04/03/2009		International Conference Presentation	1	PDF	-
20/02/2009		Half Year Results Summary	2	PDF	-
20/02/2009		Half Yearly Report and Accounts	25	PDF	-
10/02/2009		Head and Neck cancer trial 1st patient injected	2	PDF	-
30/01/2009		Appendix 4C - quarterly	5	PDF	-

Useful Information

• How and when are company announcements published on www.asx.com.au?
• * Edited text summaries are available from 1 January 1998 to 30 June 2003

Previous codes used by this company

• PSX changed to VLA
• MIV changed to PSX

Didn't find the announcement you were after? > Search again.

Viewing Company Announcements:
Users of Adobe Acrobat Reader version 6.0.0 may have difficulty accessing PDF announcements. Symptoms include slow downloads, blank documents, and small white boxes appearing in the PDF. We recommend you download the latest version of the free Adobe Acrobat Reader. To check which version you have, open Adobe Acrobat Reader, click on 'Help', then click 'About Adobe Reader 6.0'.

Home | Contact us | FAQs | Sitemap | Glossary

Terms of use | Privacy Statement | Accessibility Statement

© 2013 ASX Limited ABN 98 008 624 691

The ASX Group's activities span primary and secondary market services, including capital formation and hedging, trading and price discovery (Australian Securities Exchange); central counterparty risk transfer (ASX Clearing Corporation); and securities settlement for both the equities and fixed income markets (ASX Settlement Corporation).